Table 1 Clinicopathological characteristics of high and low NOP16 expression groups.

| Characteristic | Low expression of NOP16 | High expression of NOP16 | p |
| --- | --- | --- | --- |
| n | 187 | 187 |  |
| T stage, n (%) |  |  | 0.413 |
| T1 | 97 (26.1%) | 86 (23.2%) |  |
| T2 | 45 (12.1%) | 50 (13.5%) |  |
| T3 | 35 (9.4%) | 45 (12.1%) |  |
| T4 | 8 (2.2%) | 5 (1.3%) |  |
| N stage, n (%) |  |  | 0.122 |
| N0 | 125 (48.4%) | 129 (50%) |  |
| N1 | 4 (1.6%) | 0 (0%) |  |
| M stage, n (%) |  |  | 1.000 |
| M0 | 131 (48.2%) | 137 (50.4%) |  |
| M1 | 2 (0.7%) | 2 (0.7%) |  |
| Pathologic stage, n (%) |  |  | 0.887 |
| Stage I | 88 (25.1%) | 85 (24.3%) |  |
| Stage II | 41 (11.7%) | 46 (13.1%) |  |
| Stage III | 41 (11.7%) | 44 (12.6%) |  |
| Stage IV | 3 (0.9%) | 2 (0.6%) |  |
| Tumor status, n (%) |  |  | 0.319 |
| Tumor free | 107 (30.1%) | 95 (26.8%) |  |
| With tumor | 72 (20.3%) | 81 (22.8%) |  |
| Gender, n (%) |  |  | 0.002 |
| Female | 75 (20.1%) | 46 (12.3%) |  |
| Male | 112 (29.9%) | 141 (37.7%) |  |
| Age, n (%) |  |  | 0.232 |
| <=60 | 95 (25.5%) | 82 (22%) |  |
| >60 | 92 (24.7%) | 104 (27.9%) |  |
| Weight, n (%) |  |  | 0.767 |
| <=70 | 88 (25.4%) | 96 (27.7%) |  |
| >70 | 81 (23.4%) | 81 (23.4%) |  |
| BMI, n (%) |  |  | 0.421 |
| <=25 | 83 (24.6%) | 94 (27.9%) |  |
| >25 | 83 (24.6%) | 77 (22.8%) |  |
| Histologic grade, n (%) |  |  | 0.033 |
| G1 | 35 (9.5%) | 20 (5.4%) |  |
| G2 | 91 (24.7%) | 87 (23.6%) |  |
| G3 | 55 (14.9%) | 69 (18.7%) |  |
| G4 | 3 (0.8%) | 9 (2.4%) |  |
| AFP(ng/ml), n (%) |  |  | 0.571 |
| <=400 | 105 (37.5%) | 110 (39.3%) |  |
| >400 | 35 (12.5%) | 30 (10.7%) |  |
| Residual tumor, n (%) |  |  | 1.000 |
| R0 | 161 (46.7%) | 166 (48.1%) |  |
| R1 | 8 (2.3%) | 9 (2.6%) |  |
| R2 | 0 (0%) | 1 (0.3%) |  |
| Adjacent hepatic tissue inflammation, n (%) |  |  | 0.309 |
| None | 68 (28.7%) | 50 (21.1%) |  |
| Mild | 49 (20.7%) | 52 (21.9%) |  |
| Severe | 8 (3.4%) | 10 (4.2%) |  |
| Albumin(g/dl), n (%) |  |  | 0.035 |
| <3.5 | 27 (9%) | 42 (14%) |  |
| >=3.5 | 126 (42%) | 105 (35%) |  |
| Prothrombin time, n (%) |  |  | 0.152 |
| <=4 | 101 (34%) | 107 (36%) |  |
| >4 | 52 (17.5%) | 37 (12.5%) |  |
| Child-Pugh grade, n (%) |  |  | 0.733 |
| A | 106 (44%) | 113 (46.9%) |  |
| B | 11 (4.6%) | 10 (4.1%) |  |
| C | 1 (0.4%) | 0 (0%) |  |
| Age, median (IQR) | 60 (51, 68) | 62.5 (52, 69) | 0.332 |

Table 2 .Cox proportional hazards regression analyzed the association of NOP16 expression levels and

OS prognosis in LIHC patients

| Characteristics | Total(N) | Univariate analysis |   | Multivariate analysis |
| --- | --- | --- | --- | --- |
| Hazard ratio (95% CI) | P value | Hazard ratio (95% CI) | P value |
| T stage | 370 |  |  |  |  |  |
| T1 | 183 | Reference |  |  |  |  |
| T2 | 94 | 1.428 (0.901-2.264) | 0.129 |  | 0.000 (0.000-Inf) | 0.996 |
| T3&T4 | 93 | 2.949 (1.982-4.386) | **<0.001** |  | 0.722 (0.097-5.401) | 0.751 |
| N stage | 258 |  |  |  |  |  |
| N0 | 254 | Reference |  |  |  |  |
| N1 | 4 | 2.029 (0.497-8.281) | 0.324 |  |  |  |
| M stage | 272 |  |  |  |  |  |
| M0 | 268 | Reference |  |  |  |  |
| M1 | 4 | 4.077 (1.281-12.973) | **0.017** |  | 7.439 (0.582-95.117) | 0.123 |
| Weight | 345 |  |  |  |  |  |
| <=70 | 184 | Reference |  |  |  |  |
| >70 | 161 | 0.941 (0.657-1.346) | 0.738 |  |  |  |
| Pathologic stage | 349 |  |  |  |  |  |
| Stage I | 173 | Reference |  |  |  |  |
| Stage II | 86 | 1.417 (0.868-2.312) | 0.164 |  | 9699232.960 (0.000-Inf) | 0.996 |
| Stage III | 85 | 2.734 (1.792-4.172) | **<0.001** |  | 4.391 (0.572-33.718) | 0.155 |
| Stage IV | 5 | 5.597 (1.726-18.148) | **0.004** |  |  |  |
| Tumor status | 354 |  |  |  |  |  |
| Tumor free | 202 | Reference |  |  |  |  |
| With tumor | 152 | 2.317 (1.590-3.376) | **<0.001** |  | 1.961 (1.226-3.135) | **0.005** |
| Age | 373 |  |  |  |  |  |
| <=60 | 177 | Reference |  |  |  |  |
| >60 | 196 | 1.205 (0.850-1.708) | 0.295 |  |  |  |
| Histologic grade | 368 |  |  |  |  |  |
| G1 | 55 | Reference |  |  |  |  |
| G2 | 178 | 1.162 (0.686-1.969) | 0.576 |  |  |  |
| G3 | 123 | 1.185 (0.683-2.057) | 0.545 |  |  |  |
| G4 | 12 | 1.681 (0.621-4.549) | 0.307 |  |  |  |
| BMI | 336 |  |  |  |  |  |
| <=25 | 177 | Reference |  |  |  |  |
| >25 | 159 | 0.798 (0.550-1.158) | 0.235 |  |  |  |
| AFP(ng/ml) | 279 |  |  |  |  |  |
| <=400 | 215 | Reference |  |  |  |  |
| >400 | 64 | 1.075 (0.658-1.759) | 0.772 |  |  |  |
| Gender | 373 |  |  |  |  |  |
| Female | 121 | Reference |  |  |  |  |
| Male | 252 | 0.793 (0.557-1.130) | 0.200 |  |  |  |
| Adjacent hepatic tissue inflammation | 236 |  |  |  |  |  |
| None | 118 | Reference |  |  |  |  |
| Mild&Severe | 118 | 1.194 (0.734-1.942) | 0.475 |  |  |  |
| NOP16 | 373 |  |  |  |  |  |
| Low | 187 | Reference |  |  |  |  |
| High | 186 | 1.462 (1.034-2.068) | **0.032** |  | 1.763 (1.115-2.790) | **0.015** |